blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2170333

EP2170333 - RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.12.2013
Database last updated on 14.06.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2012/28]
Former [2010/19]For all designated states
Gilead Palo Alto, Inc.
333 Lakeside Drive
Foster City CA 94404 / US
Former [2010/14]For all designated states
Gilead Palo Alto, Inc.
3172 Porter Drive
Palo Alto, CA 94304 / US
Inventor(s)01 / BLACKBURN, Brent
633 Almond Avenue
Los Altos, CA 94022 / US
02 / JERLING, Marcus
Stavgardsgatan 30
S-167 56 Bromma / SE
03 / WOLFF, Andrew
2140 Taylor Street 803
San Francisco, CA 94133 / US
 [2010/14]
Representative(s)Schnappauf, Georg, et al
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[N/P]
Former [2013/08]Schnappauf, Georg, et al
Dr. Volker Vossius
Patent- und Rechtsanwaltskanzlei
Geibelstrasse 6
81679 München / DE
Former [2010/14]Schnappauf, Georg, et al
Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6
81679 München / DE
Application number, filing date08732776.324.03.2008
[2010/14]
WO2008US58063
Priority number, dateUS20070941210P31.05.2007         Original published format: US 941210 P
[2010/14]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008150565
Date:11.12.2008
Language:EN
[2008/50]
Type: A2 Application without search report 
No.:EP2170333
Date:07.04.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 11.12.2008 takes the place of the publication of the European patent application.
[2010/14]
Type: B1 Patent specification 
No.:EP2170333
Date:20.02.2013
Language:EN
[2013/08]
Search report(s)International search report - published on:EP02.04.2009
ClassificationIPC:A61K31/495, A61P9/10, G01N33/68, A61K9/08, A61K9/22
[2012/16]
CPC:
A61K31/495 (EP,KR,US); A61P9/00 (EP); A61P9/10 (EP);
G01N33/68 (KR); G01N33/74 (EP,US); G01N2333/58 (EP,US)
Former IPC [2010/14]A61K31/495, A61P9/10, G01N33/68
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/14]
Extension statesAL17.12.2009
BA17.12.2009
MK17.12.2009
RS17.12.2009
TitleGerman:RANOLAZIN FÜR ERHÖHTES NATRIURETISCHES PEPTID VOM GEHIRN-TYP[2010/14]
English:RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE[2010/14]
French:UTILISATION DE RANOLAZINE POUR PEPTIDE CÉRÉBRAL NATRIURÉTIQUE ÉLEVÉ[2010/14]
Entry into regional phase17.12.2009National basic fee paid 
17.12.2009Designation fee(s) paid 
17.12.2009Examination fee paid 
Examination procedure06.12.2008Request for preliminary examination filed
International Preliminary Examining Authority: EP
17.12.2009Amendment by applicant (claims and/or description)
17.12.2009Examination requested  [2010/14]
30.07.2010Despatch of a communication from the examining division (Time limit: M03)
02.11.2010Reply to a communication from the examining division
24.04.2012Communication of intention to grant the patent
13.08.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.08.2012Fee for grant paid
13.08.2012Fee for publishing/printing paid
31.10.2012Communication of intention to grant the patent
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.07.2010
Opposition(s)21.11.2013No opposition filed within time limit [2014/05]
Fees paidRenewal fee
25.03.2010Renewal fee patent year 03
29.03.2011Renewal fee patent year 04
26.03.2012Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.03.2008
AT20.02.2013
BE20.02.2013
CY20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
MT20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
TR20.02.2013
IE24.03.2013
LU24.03.2013
CH31.03.2013
LI31.03.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
[2015/34]
Former [2015/32]AT20.02.2013
BE20.02.2013
CY20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
MT20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
TR20.02.2013
IE24.03.2013
CH31.03.2013
LI31.03.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2014/32]AT20.02.2013
BE20.02.2013
CY20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
MT20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
IE24.03.2013
CH31.03.2013
LI31.03.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2014/08]AT20.02.2013
BE20.02.2013
CY20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
IE24.03.2013
CH31.03.2013
LI31.03.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2014/07]AT20.02.2013
BE20.02.2013
CY20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
IE24.03.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/52]AT20.02.2013
BE20.02.2013
CY20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/49]AT20.02.2013
BE20.02.2013
CZ20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
NL20.02.2013
PL20.02.2013
RO20.02.2013
SE20.02.2013
SI20.02.2013
SK20.02.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/48]AT20.02.2013
BE20.02.2013
DK20.02.2013
EE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
NL20.02.2013
PL20.02.2013
SE20.02.2013
SI20.02.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/47]AT20.02.2013
BE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
PL20.02.2013
SE20.02.2013
SI20.02.2013
MC31.03.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/41]AT20.02.2013
BE20.02.2013
FI20.02.2013
HR20.02.2013
LT20.02.2013
LV20.02.2013
PL20.02.2013
SE20.02.2013
SI20.02.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/40]AT20.02.2013
BE20.02.2013
FI20.02.2013
LT20.02.2013
LV20.02.2013
PL20.02.2013
SE20.02.2013
SI20.02.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
PT20.06.2013
Former [2013/38]AT20.02.2013
BE20.02.2013
FI20.02.2013
LT20.02.2013
LV20.02.2013
PL20.02.2013
SE20.02.2013
SI20.02.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
Former [2013/37]AT20.02.2013
FI20.02.2013
LT20.02.2013
PL20.02.2013
SE20.02.2013
SI20.02.2013
BG20.05.2013
NO20.05.2013
GR21.05.2013
IS20.06.2013
Former [2013/36]AT20.02.2013
LT20.02.2013
PL20.02.2013
SE20.02.2013
BG20.05.2013
NO20.05.2013
IS20.06.2013
Former [2013/34]LT20.02.2013
SE20.02.2013
BG20.05.2013
NO20.05.2013
IS20.06.2013
Former [2013/33]LT20.02.2013
NO20.05.2013
Cited inInternational search[A]  - HEART PROTECTION STUDY COLLABORATIVE GROUP, "N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, (20070117), vol. 49, no. 3, ISSN 0735-1097, pages 311 - 319, XP005834244 [A] 1-32 * abstract *

DOI:   http://dx.doi.org/10.1016/j.jacc.2006.08.052
 [A]  - MORROW DAVID A ET AL, "Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, (20030416), vol. 41, no. 8, ISSN 0735-1097, pages 1264 - 1272, XP002484190 [A] 1-32 * abstract *

DOI:   http://dx.doi.org/10.1016/S0735-1097(03)00168-2
 [A]  - JERNBERG TOMAS ET AL, "N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, (20020807), vol. 40, no. 3, ISSN 0735-1097, pages 437 - 445, XP002510229 [A] 1-32 * abstract page 444, column 1, lines 16-21 *

DOI:   http://dx.doi.org/10.1016/S0735-1097(02)01986-1
 [AD]  - MORROW DAVID A ET AL, "Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes - The MERLIN-TIMI 36 randomized trial", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, (20070425), vol. 297, no. 16, ISSN 0098-7484, pages 1775 - 1783;E1, XP002480268 [AD] 1-32 * the whole document *

DOI:   http://dx.doi.org/10.1001/jama.297.16.1775
 [PX]  - MORROW DAVID A ET AL, "B-type natriuretic peptide and the effect of ranolazine in patients with non-ST elevation acute coronary syndromes in the MERLIN-TIMI 36 trial", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, (20071001), vol. 116, no. 16, Suppl. S, ISSN 0009-7322, page 382, XP008092823 [PX] 1-32 * the whole document *
 [PX]  - MEGA JESSICA L ET AL, "Anti-ischemic effects of ranolazine in women: Results from the randomized, placebo-controlled MERLIN-TIMI 36 trial", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, (20071001), vol. 116, no. 16, Suppl. S, ISSN 0009-7322, page 539, XP008091380 [PX] 1-32 * the whole document *
ExaminationWO0013687
    - NEWBY L KRISTIN ET AL, "Does ranolazine have a place in the treatment of acute coronary syndromes?", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, UNITED STATES, (20070425), vol. 297, no. 16, ISSN 1538-3598, pages 1824 - 1825, XP008100304
    - STANLEY W C, "RANOLAZINE: NEW APPROACH FOR THE TREATMENT OF STABLE ANGINA PECTORIS", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, FUTURE DRUGS, LONDON, GB LNKD- DOI:10.1586/14779072.3.5.821, (20050901), vol. 3, no. 5, ISSN 1477-9072, pages 821 - 829, XP009062744

DOI:   http://dx.doi.org/10.1586/14779072.3.5.821
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.